Cu-Tech Report issue

For profit Phase 2 Phase 3
Founded: Mountain Lakes NJ United States (1993)
Status: Acquired by Synteract, Inc. (2018) → now Syneos Health (2020)

Organization Overview

First Clinical Trial
2009
NCT01243450
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cu-Tech, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

tretinoin (Retin-A) (1 trial)

Drugs in Phase 2 Trials (2)

butenafine (mentax) (1 trial)

Dapansutrile (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 2)

Tinea (Phase 2)

Tinea Pedis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3